Introduction
============

The incidence of cutaneous melanoma is increasing ([@b1-or-37-02-0737],[@b2-or-37-02-0737]). Although much progress has been made in terms of immuno- and chemotherapy, the mortality rate for patients with melanoma remains very high, as it is a very aggressive disease ([@b3-or-37-02-0737],[@b4-or-37-02-0737]). Cutaneous melanoma is influenced by genetic and environmental factors.

The dysregulation of the RAS/RAF/MEK/extracellular signal regulated kinase (ERK) pathway plays a key role in the pathogenesis of several human cancers ([@b5-or-37-02-0737]--[@b8-or-37-02-0737]); mutations at upstream membrane receptors, NRAS and BRAF, as well as genes in other pathways \[e.g., phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN) and AKT\], which serve to regulate Raf activity, promote constitutive ERK signalling, stimulating proliferation and survival and providing essential tumour growth and maintenance functions ([@b9-or-37-02-0737]). In melanoma, both the RAS-RAF-MEK-ERK (MAPK) and the PI3K-AKT (AKT) signalling pathways are constitutively activated through multiple mechanisms ([@b9-or-37-02-0737]). Mutations of the BRAF gene have been proposed to contribute to the development of melanoma ([@b10-or-37-02-0737]--[@b12-or-37-02-0737]). The increased activity of the MAPK pathway prevents apoptosis and induces cell cycle progression ([@b13-or-37-02-0737]). The most frequent BRAF mutation, which accounts for \<60% of melanoma tumours with BRAF activation, is a glutamic acid for valine substitution at codon 600 in exon 15, (Val600Glu; BRAF^V600E^) ([@b9-or-37-02-0737]).

The melanoma microenvironment is a dynamic system, largely orchestrated, not only by malignant cells, but also from the stroma, that includes inflammatory cells, immune cells, fibroblasts, soluble molecules and the surrounding extracellular matrix (ECM) ([@b14-or-37-02-0737],[@b15-or-37-02-0737]). The perturbations of this network may interfere directly or indirectly with melanocyte-keratinocyte and/or melanocyte-ECM relationships and may impact on melanoma diagnosis, prognosis and treatment. Melanomagenesis requires the cooperation of several molecules playing a role in the tumour microenvironment ([@b16-or-37-02-0737]--[@b18-or-37-02-0737]).

In this context, the ECM plays an active role during melanoma progression, promoting the epigenetic transdifferentiation of melanocytes toward an invasive melanoma cell-like phenotype ([@b19-or-37-02-0737],[@b20-or-37-02-0737]). The invasion of tumour cells is a complex multistage process that includes proteolysis in the pericellular and stromal compartments, and has been shown to largely contribute to altering the tumour microenvironment, essential in promoting melanoma invasion, the degradation of basement membranes and remodeling of the ECM by proteolytic enzymes, such as matrix metalloproteinases (MMPs). MMPs, particularly MMP-2 and MMP-9 play a major role in the regulation of cancer cell migration, ECM invasion and metastasis through autocrine or paracrine pathways ([@b21-or-37-02-0737],[@b22-or-37-02-0737]). The expression of MMP-9 has been shown to be associated withthe intragenic hypermethylation of the *MMP-9* gene in melanoma ([@b23-or-37-02-0737]). Furthermore, its expression is regulated by lymphocytes and monocytes activated mostly at the transcriptional level by a variety of growth factors, cytokines and chemokines ([@b24-or-37-02-0737]--[@b26-or-37-02-0737]).

Numerous studies have suggested that the overexpression of MMP-2 and MMP-9 is associated with an aggressive behaviour, dissemination, advanced stages and poor prognosis in various types of cancer, including melanoma ([@b22-or-37-02-0737],[@b26-or-37-02-0737]--[@b35-or-37-02-0737]). Their activation in human cancer may be associated with the release of osteopontin (OPN), a secreted multifunctional phosphoprotein that has been implicated as an important mediator of tumour metastasis ([@b36-or-37-02-0737]--[@b39-or-37-02-0737]). Several reports have indicated that OPN, a matricellular protein found in the tumour microenvironment and expressed by host and cancer cells, may regulate tumourigenesis, cancer progression and metastasis ([@b40-or-37-02-0737]--[@b42-or-37-02-0737]).

In detail, OPN expression has been linked to tumourigenesis and metastasis in a wide range of cancers, including melanoma ([@b43-or-37-02-0737]--[@b48-or-37-02-0737]). Previous studies have suggested a role for increased OPN tissue expression in the malignant transformation of melanocytes, and as an important determinant of melanoma progression ([@b49-or-37-02-0737],[@b50-or-37-02-0737]). The aggressiveness of malignant melanoma has been associated with a high OPN expression and its overexpression correlates with advanced tumour stages ([@b50-or-37-02-0737],[@b51-or-37-02-0737]). OPN enhances the migration and invasion of malignant tumour cells possibly through both the inhibition of apoptosis and by regulating the activities of MMP-2 and MMP-9, which degrade the ECM ([@b36-or-37-02-0737],[@b38-or-37-02-0737],[@b39-or-37-02-0737]).

Previous experimental data have suggested that in melanoma cell lines, OPN upregulates MMP-9 activity, modulating multiple signalling pathways via focal adhesion kinase (FAK), ERK and nuclear factor-κB (NF-κB) ([@b52-or-37-02-0737]--[@b56-or-37-02-0737]) that regulate cytoskeletal organization, cell motility, cell growth, and ultimately control cell migration, ECM invasion and tumour growth ([@b36-or-37-02-0737]).

In this context, it has been indicated that NF-κB may be a key player in OPN and MMP-9 activation. However, whether NF-κB plays a role in the development and progression melanoma of in association with the OPN/MMP-9 axis according to the BRAF^V600E^ mutation status has not been investigated in detail to date. Thus, in the present study, OPN/MMP-9 pathway activation was examined in patients with melanoma, particularly those harbouring BRAF^V600E^ mutations. Furthermore, OPN/MMP-9 inhibition was observed in peripheral blood mononuclear cells (PBMCs) isolated from patients with melanoma following treatment with NF-κB inhibitor.

Materials and methods
=====================

Plasma samples from 148 patients with melanoma at different stages of the disease were collected for use in the present study. Samples were obtained prior to surgery, and were collected from the Unit of Dermatology, University of Messina (Messina, Italy) and stored until analyses at the Department of Biomedical and Biotechnological Sciences, University of Catania (Catania, Italy). Tumour samples from all patients were grouped according to the mutation status of BRAF^V600E^. The number of patients with melanoma harbouring the BRAF^V600E^ mutation was 86, and the remaining 62 patients were BRAF^WT^. PBMCs were obtained from 29 patients with melanoma harbouring the BRAF^V600E^ mutation. As the control group, PBMCs and plasma samples from 53 healthy subjects were obtained and stored. Another set of plasma samples from 18 out of the 148 patients with melanoma was obtained at 3 months following surgery. The scientific Ethics Committee of the Policlinic University of Messina (Messina, Italy) approved all the procedures. All participants provided written consent prior to blood collection. Blood was centrifuged (300 × g for 10 min at 4°C) and the separated plasma was placed in aliquots and stored at −80°C until analysis.

### Plasma assays of OPN and MMP-9

The OPN and MMP-9 plasma concentrations were measured using ELISA kits (R&D Systems Europe, Ltd., Abingdon, UK). The MMP-9 assays recognised both pro- and active forms. Plasma samples were diluted and the immunoassay was performed according to the instructions of the manufacturer. All assays were carried out in triplicate. The minimum detectable dose of OPN and MMP-9 was \<0.024 and 0,156 ng/ml, respectively. The optical density was measured at 450 nm using a microplate reader (Thermo Labsystems, Santa Rosa, CA, USA). The activities of MMP-9 were measured using specific Biotrak MMP-9 activity assay kits \[Amersham Pharmacia Biotech (UK) Ltd., Little Chalfont, UK\] according to the manufacturer\'s instructions. The appropriate standards were included in each assay. In order to measure the total content of the MMPs, the activation of the pro-form of the MMPs was performed using p-aminophenylmercuric acetate (APMA; Sigma-Aldrich Co. LLC. St. Louis, MO, USA).

### Chemicals

Dehydroxymethylepoxyquinomycin (DHMEQ), a new NF-κB inhibitor, kindly provided by Professor Kazuo Umezawa (Keio University, Kanagawa, Japan), was synthesised as previously described ([@b57-or-37-02-0737]). All other chemicals were purchased from Sigma-Aldrich Co. (Milan, Italy).

### Isolation of PBMCs and analysis of NF-κB p65 activity and MMP-9 production

PBMCs were obtained using a Ficoll gradient. Following isolation, PBMC pellets were collected and stored immediately at −80°C until analysis. PBMCs (1×10^6^ cells/ml), from patients with melanoma and healthy controls, were cultured in RPMI-1640 medium supplemented with 1% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco Life Technologies, Carlsbad, CA, USA). MMP-9 and NF-κB p65 activity was analysed in the supernatants and nuclear extract of PBMCs isolated from 29 patients with melanoma harbouring the BRAF^V600E^ mutation and 53 control patients. The PBMCs (following overnight incubation in serum-free medium) were stimulated with or without 100 ng/ml of recombinant human OPN (R&D Systems, Inc., Minneapolis, MN, USA) for 24 h (each experimental condition was carried out in triplicate), with or without pre-incubation (1 h) with DHMEQ (10 µg/ml). The concentration of MMP-9 was determined using the human MMP-9 ELISA kit (R&D Systems, Inc.) following the short-term culture of the isolated PBMCs.

For the measurement of NF-κB activation, nuclear fractions were prepared from the PBMCs (5--7×10^6^ cells per extraction) during batch processing using a Nuclear Extract kit (Active Motif, Rixensart, Belgium). The binding of NF-κB to its consensus DNA sequence was measured by ELISA using a Trans-AM™ NF-κB p65 Transcription Factor Assay kit (Active Motif), according to the instructions of the manufacturer. Briefly, nuclear extract protein (5 µg/well) was incubated in 96-well plates coated with immobilised oligonucleotide (5′-AGTTGAGGGGACTTTCCCAGGC-3′) containing a consensus (5′-GGGACTTTCC-3′) binding site for the p65 subunit of NF-κB. NF-κB binding to the target oligonucleotide was detected by incubation with primary antibody specific for the activated form of p65 (Active Motif; Cat. no. 40096), visualised by anti-IgG horseradish peroxidase-conjugated secondary antibody (Active Motif; Cat. no. 15015). At the end of the incubation period, the developing and stop solution were added, and an optical density of 450 nm (OD 450) was read on a Wallac Victor 1420 multilabel counter (PerkinElmer, Inc., Shelton, CT, USA).

### Statistical analysis

The statistical methods have been previously reported in detail in the study by Polesel *et al* ([@b57-or-37-02-0737]). Briefly, the values of plasma OPN, MMP-9 and MMP-9 activity were described as the median, minimum and maximum values. Differences in the distribution of OPN, MMP-9 and MMP-9 activity between the healthy controls and the melanoma cases were examined using a non-parametric Wilcoxon test or non-parametric χ^2^ tests. Correlations between markers were evaluated by means of Pearson\'s correlation scores. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated using the multiple logistic regression models adjusted for gender and age. A two-tailed value of P\<0.05 was considered to indicate a statistically significant difference. One-way ANOVA was also used to compare the OPN, MMP-9 and MMP-9 levels in the patients with melanoma who were BRAF^WT^ and BRAF^MUT^ according to the clinicopathological characteristics.

Results
=======

The socio-demographic characteristics of the cases and the controls, and the distribution of melanoma cases according to clinical characteristics at diagnosis, are presented in [Table I](#tI-or-37-02-0737){ref-type="table"}. The majority of cases were nodular melanoma (54%), without ulcerations (55.4%), and with negative sentinel lymph nodes (62.8%). Breslow thickness was \>4 mm for 33 cases (22.3%) and the invasion of the reticular dermis or subcutaneous fat had occurred in 17.6% of cases.

### Plasma levels of OPN and MMP-9

The plasma levels of OPN, MMP-9 and MMP-9 activity are shown in [Fig. 1](#f1-or-37-02-0737){ref-type="fig"}. For all considered markers, the levels were considerably higher among the melanoma cases than the healthy controls, particularly for those who had a positive sentinel lymph node and nodular histotype ([Fig. 1](#f1-or-37-02-0737){ref-type="fig"}). [Table II](#tII-or-37-02-0737){ref-type="table"} shows the mean concentrations of these proteins according to the BRAF^V600E^ status. Higher levels of MMP-9 and MMP-9 activity were detected among the melanoma samples harbouring the BRAF^V600E^ mutation compared to those which were BRAF^WT^; however, no significant differences were observed in the OPN levels between these two groups of patients ([Table II](#tII-or-37-02-0737){ref-type="table"}). As expected, higher MMP-9 levels were also associated with other negative prognostic factors, such as sentinel lymph node involvement, Breslow thickness, Clark\'s level and ulceration ([Table II](#tII-or-37-02-0737){ref-type="table"}). Linear correlations between OPN, MMP-9 and MMP-9 activity were high (r\>0.50) among both melanoma cases and healthy subjects ([Fig. 2](#f2-or-37-02-0737){ref-type="fig"}).

The OPN and MMP-9 plasma levels, and MMP-9 activity were monitored in 18 melanoma cases who were followed-up actively ([Table III](#tIII-or-37-02-0737){ref-type="table"}). At cancer diagnosis, the levels of the three markers were 3- to −6-fold higher in the patients with melanoma than in the healthy controls. However, at 3 months post-surgery, the levels of OPN and MMP-9, and MMP-9 activity were significantly decreased and were comparable to those of the healthy controls. Of note, the melanoma cases with a positive sentinel lymph node maintained a higher expression of OPN than the negative ones (45.6 and 34.3, respectively) ([Table III](#tIII-or-37-02-0737){ref-type="table"}). Furthermore, in 3 patients with melanoma with the documented progression of disease after 3 months from the first surgery, the mean values of all markers increased (data not shown).

### Production of OPN and MMP-9 and NF-κB p65 activity from PBMCs

As PBMCs are the main source of the production of both OPN and MMP-9 ([@b39-or-37-02-0737],[@b59-or-37-02-0737],[@b60-or-37-02-0737]), we then determined the production of OPN and MMP-9 in PBMCs from 53 healthy donors and 29 patients with melanoma that were cultured for 24 h with or without OPN. The secretion levels of OPN and MMP-9 in the supernatants of the PBMCs from the patients with melanoma and healthy donors showed the same trend to those obtained in plasma ([Table IV](#tIV-or-37-02-0737){ref-type="table"}).

PBMCs from both the patients with melanoma and the controls were treated with OPN in order to determine the direct association with the increase in the MMP-9 levels in the supernatant. As expected, following treatment with OPN, the levels of MMP-9 were higher in the patients with melanoma than in the controls ([Fig. 3A](#f3-or-37-02-0737){ref-type="fig"}). A similar trend was observed by analysing the activity of NF-κB p65 ([Fig. 3B](#f3-or-37-02-0737){ref-type="fig"}). The PBMCs from the patients with melanoma and the controls were treated with the inhibitor of NF-κB (DHMQ) to demonstrate its effect on OPN, MMP-9 and NF-κB ([Fig. 4](#f4-or-37-02-0737){ref-type="fig"}). The results revealed that treatment with DHMQ did not affect the release of OPN, MMP-9 and NF-κB p65 activity in the PBMCs from healthy donors, whereas a significant decrease in the levels each protein was observed in the PBMCs from the patients with melanoma ([Fig. 4](#f4-or-37-02-0737){ref-type="fig"}). The PBMCs from the patients with melanoma and the healthy controls were also treated with both OPN and DHMQ in order to examine their effects on MMP-9 and NF-κB. In this case, the MMP-9 release and NF-κB p65 activity were markedly decreased in the PBMCs from both the controls and patients with melanoma ([Fig. 4](#f4-or-37-02-0737){ref-type="fig"}). In parallel, MMP-9 and NF-κB p65 activity were measured in PBMCs from patients with melanoma with or without BRAF^V600E^ mutation. The results revealed that both NF-κB p65 activity and MMP-9 release were higher in the PBMCs from patients with melanoma harbournig the BRAF^V600E^ mutation. Treatment with OPN further increased MMP-9 release and NF-κB p65 activity in both the controls and melanoma cases. The MMP-9 release and NF-κB p65 activity were both decreased following treatment with DHMEQ ([Fig. 5](#f5-or-37-02-0737){ref-type="fig"}).

Discussion
==========

Melanoma is a complex process that involves the deregulation of interacting proteins and genes, which in turn are responsible for the proliferation, invasion, angiogenesis of tumour cells, and finally the evasion of host immune systems ([@b61-or-37-02-0737]). A prerequisite for melanoma progression, in addition to the ability of the cells to leave the cellular bond and to migrate, is the degradation of components of the ECM ([@b62-or-37-02-0737]). Tumour cells and their microenvironment mutually influence each other during tumour development and progression ([@b63-or-37-02-0737]). Uncontrolled proliferation is a cancer hallmark, a result of the activation various oncogenic and angiogenic molecules, and of the crosstalk between many signalling pathways. Previous studies have strongly supported the crucial role of OPN in tumour progression through the regulation of multiple signalling events, including those critically dependent on MMP bioavailability ([@b36-or-37-02-0737]--[@b40-or-37-02-0737],[@b52-or-37-02-0737]--[@b55-or-37-02-0737]). OPN contributes to aggressiveness both through the inhibition of apoptosis and the activation of various matrix-degrading proteases, such as the activation of MMP-2 and MMP-9 ([@b37-or-37-02-0737],[@b64-or-37-02-0737]). Although several studies have demonstrated that OPN and MMP-9 are implicated in the development and progression of several types of cancer ([@b22-or-37-02-0737],[@b34-or-37-02-0737],[@b35-or-37-02-0737],[@b38-or-37-02-0737],[@b43-or-37-02-0737],[@b46-or-37-02-0737],[@b49-or-37-02-0737]--[@b51-or-37-02-0737],[@b65-or-37-02-0737]), it is important to investigate how these proteins may be involved in the molecular mechanism linked with melanoma development. Understanding such mechanisms may provide further insight into the discovery of novel therapeutic approaches.

The results of the present study, comprising the analysis of well-defined clinical material, including \>100 blood samples from patients with melanoma, revealed a significant increase in OPN levels in the patients with melanoma compared to the heathy subjects. Furthermore, the highest levels of OPN were directly associated with ulceration, tumour thickness and nodular type. In melanoma, OPN expression is significantly associated with reduced survival and with a poor clinical outcome ([@b48-or-37-02-0737],[@b66-or-37-02-0737]).

In agreement with other reports demonstrating that MMP-9 is implicated in the regulation of tumour cell migration and in the development and metastasis ([@b22-or-37-02-0737],[@b26-or-37-02-0737],[@b27-or-37-02-0737]), our data indicated that higher MMP-9 levels, as well as OPN, are strongly associated with positive sentinel lymph-node and tumour thickness, markers of malignancy. A positive correlation between OPN and MMP-9, including MMP-9 activity, was found in both melanoma cases and healthy subjects.

Intriguingly, the levels of OPN and MMP-9 were monitored in 18 melanoma cases in a follow-up period of 3 months. Prior to surgery, these 18 cases expressed both markers at 3- to −6-fold higher levels than the healthy controls. At 3 months psot-surgery, these levels were significantly decreased. These results indicate the strong association of these molecules with the clinical manifestation of the disease. These data were confirmed by further experiments conducted on PBMCs from 53 healthy donors and 29 patients with melanoma that were cultured for 24 h with or without OPN. Stimulation of the PBMCs with OPN increased the production of MMP-9, particularly in the patients with melanoma. These data suggest that the OPN/MMP-9 pathway is associated with the transformation and progression of melanoma. The impact of OPN regulating MMP-9 is cell type-dependent and involves a variety of overlapping intracellular signalling pathways.

Therefore, the mechanism through which OPN mediates MMP-9 activation in melanoma and consequently enhances tumour aggressiveness may be associated with NF-κB activation. OPN regulates MMP activity in various ways. It can bind MMP-9 and promote its activation through an NF-κB/IκBa/IKK signalling pathway ([@b54-or-37-02-0737]). Accordingly, the treatment of PBMCs from healthy donors and patients with melanoma with OPN confirmed the production of NF-κB activity in patients with melanoma. NF-κB activation has been connected with multiple processes of oncogenesis, including the control of apoptosis, cell cycle, differentiation and cell migration ([@b67-or-37-02-0737],[@b68-or-37-02-0737]). We have observed that the activity of the NF-κB p65 subunit in PBMCs from patients with melanoma was higher when compared with that of the controls. We also evaluated the effect of DHMEQ, a specific inhibitor of NF-κB ([@b69-or-37-02-0737]--[@b71-or-37-02-0737]), to determine whether NF-κB inhibition was associated with the decrease of OPN and MMP-9 and to demonstrate the direct role of the NF-κB-regulated OPN and MMP-9 markers in patients with melanoma. Additional experiments with PBMCs from the two groups revealed that the MMP-9 levels decreased following treatment with both OPN and DHMEQ, suggesting a strong association between OPN and MMP-9 and their upregulation mediated by NF-κB. Intriguingly, such an activation was associated with melanoma diagnosed in patients harbouring the BRAF^V600E^ mutation. In the present study, through the analysis of each patient\'s medical file, BRAF^V600E^ mutation was detected in 58% of the patients with melanoma. The MMP-9 plasma levels were higher in the patients with such a mutation compared with those who were BRAF^WT^; furthermore, the association of higher plasma levels of MMP-9 with several negative prognostic factors supports the notion that MMP-9 may be implicated in the aggressiveness of melanoma.

Overall, the findings of the present study indicate that OPN and MMP-9 expression and their upstream regulator, NF-κB, may be considered promising markers for melanoma development and may thus be useful targets for therapeutic interventions.
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![Secretion of (A) osteopontin (OPN), (B) matrix metalloproteinase (MMP)-9 and (C) nuclear factor-κB (NF-κB), in PBMCs from healthy donors and melanoma cases treated with NF-κB inhibitor (DHMQ) treated with or without recombinant human osteopontin (rhOPN). \*P\<0.05 compared to DHMEQ-treated cells; \*\*P\<0.05 compared to rhOPN + DHMEQ-treated cells. OD, optical density; PBMCs, peripheral blood mononuclear cells.](OR-37-02-0737-g03){#f4-or-37-02-0737}
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###### 

Distribution of 148 melanoma cases 53 healthy controls according to sociodemografic variables and main clinical characteristics.

                                           Melanoma cases   Controls     
  ---------------------------------------- ---------------- ------------ ---------
  Gender                                                                 
    Male                                   90 (60.8)        25 (47.2)    
    Female                                 58 (39.2)        28 (52.8)    P=0.09
  Age, years                                                             
    \<50                                   32 (21.6)        27 (50.9)    
    50--59                                 52 (35.1)        18 (34.0)    
    ≥60                                    64 (43.2)          8 (15.1)   P\<0.01
  Hystological subtype                                                   
    Suderficially spreading                68 (46.0)                     
    Nodular                                80 (54.0)                     
  Breslow thickness, mm                                                  
    ≤2.0                                   73 (49.3)                     
    2.1--4.0                               42 (28.4)                     
    \>4.0                                  33 (22.3)                     
  Clark\'s level                                                         
    2. Invasion of basal layer epidermis   64 (43.2)                     
    3. Invasion of papillary dermis        58 (39.2)                     
    4. Invasion of reticular dermis        14 (9.5)                      
    5. Invasion of subcutaneous fat        12 (8.1)                      
  Ulcerated lesion                                                       
    No                                     82 (55.4)                     
    Yes                                    61 (41.2)                     
    Not evaluated                          5 (3.4)                       
  Sentinel lymphonode                                                    
    Negative                               93 (62.8)                     
    Positive                               55 (37.2)                     
  BRAF                                                                   
    Wild-type                              62 (41.9)                     
    Mutated                                86 (58.1)                     

###### 

Mean concentration of OPN and MMP-9, and MMP-9^[a](#tfn1-or-37-02-0737){ref-type="table-fn"}^ anctivity in 148 cases of menaloma according to clinopathological characteristics.

                            OPN     MMP-9                                                  MMP-9 activity                                                                 
  ------------------------- ------- ------------------------------------------------------ ---------------- ------------------------------------------------------ ------ -----------------------------------------------------
  Overall                   142.7   148.5                                                  128.0            154.1^[d](#tfn4-or-37-02-0737){ref-type="table-fn"}^   2.93   4.21^[d](#tfn4-or-37-02-0737){ref-type="table-fn"}^
  Hystological type                                                                                                                                                       
    Superficial spreading   134.1   131.4                                                  121.0            133.3                                                  2.39   3.33^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^
    Nodular                 150.7   162.1                                                  134.5            170.6^[d](#tfn4-or-37-02-0737){ref-type="table-fn"}^   3.44   4.91^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^
  Sentinel lymph node                                                                                                                                                     
    Negative                131.8   132.8                                                  118.3            133.1^[b](#tfn2-or-37-02-0737){ref-type="table-fn"}^   2.56   3.12^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^
    Positive                171.5   168.4                                                  153.6            180.6^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^   3.90   5.59^[b](#tfn2-or-37-02-0737){ref-type="table-fn"}^
  Breslow thickness                                                                                                                                                       
    ≤2 mm                   124.9   116.8                                                  114.6            119.8                                                  2.42   2.81
    \>2 mm                  177.5   167.3^[b](#tfn2-or-37-02-0737){ref-type="table-fn"}^   154.1            174.4^[d](#tfn4-or-37-02-0737){ref-type="table-fn"}^   3.93   5.05^[b](#tfn2-or-37-02-0737){ref-type="table-fn"}^
  Clark\'s level                                                                                                                                                          
    2--3                    137.2   135.6                                                  124.1            142.1^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^   2.77   3.69^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^
    4--5                    221.5   186.2^[b](#tfn2-or-37-02-0737){ref-type="table-fn"}^   183.5            189.0                                                  5.30   5.74
  Ulceration                                                                                                                                                              
    No                      129.5   135.4                                                  116.4            136.8^[b](#tfn2-or-37-02-0737){ref-type="table-fn"}^   2.60   3.74^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^
    Yes                     161.9   163.3                                                  144.8            174.8^[d](#tfn4-or-37-02-0737){ref-type="table-fn"}^   3.40   4.87^[c](#tfn3-or-37-02-0737){ref-type="table-fn"}^

Differences were examined by ANOVA, accounting for gender and age. Significance levels are indicated as follows:

\<0.05

\<0.01

\<0.001. OPN, osteopontin; MMP-9, matrix metalloproteinase-9.

###### 

Mean values and standrd deviation (SD) of OPN and MMP-9 levels, and MMP-9 activity in 53 controls and 18 melanoma cases at diagnosis and at 3 months post-surgery.

                             Time of markes evaluation (mean ± SD)   
  -------------------- ----- --------------------------------------- -------------
  OPN                                                                
    Controls           53      42.3 (25.3)                           
    Melanoma, SL Neg     4   189.0 (14.6)                            34.3 (14.5)
    Melanoma, SL Pos   14    208.1 (25.5)                            45.6 (15.8)
  MMP-9                                                              
    Controls           53      36.6 (14.2)                           
    Melanoma, SL Neg     4   162.6 (31.3)                            30.0 (9.0)
    Melanoma, SL Pos   14    186.6 (17.7)                            31.4 (10.9)
  MMP-9 activity                                                     
    Controls           53    1.18 (0.69)                             
    Melanoma, SL Neg     4   3.52 (1.32)                             1.14 (0.48)
    Melanoma, SL Pos   14    5.65 (1.33)                             1.40 (0.57)

SL, sentinel lymphnode; OPN, osteopontin; MMP-9, matrix metalloproteinase-9; SL Neg, sentinel lymph node negative; SL Pos, sentinel lymph node positive.

###### 

OPN, MMP-9, NF-κB basal values in PBMCs from the controls and patients with melanoma.

  PBMCs                Controls    Melanoma
  -------------------- ----------- -----------
  OPN ng/ml            0.93±0.48   8.4±3.5
  MMP-9 ng/ml            2.5±1.1   13.1±3.7
  NF-κB p65 activity   0.15±0.05     0.8±0.2

OPN, osteopontin; MMP-9, matrix metalloproteinase-9; NF-κB, nuclear factor-κB; PBMCs, peripheral blood mononuclear cells.

[^1]: Joint senior authorship
